13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • NIMO

    Acronym: 

    NIMO

    ACTRN/NCT /ethics: 

    NCT02041819

    Scientific title: 

    A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus

    Summary of trial and patient characteristics

    Cancer Type Head and Neck, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II Tumour Stream Oesophogeal
    Age Range 18-75 years Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Head and Neck, Stomach & Oesophageal
    Trial Type Treatment
    Phase Phase II
    Age Range 18-75 years
    Sex Both
    Molecular Target
    Tumour Stream Oesophogeal
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Nimotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor (EGFR),has been shown to be effective and safe in some studies with head-neck cancers.Nab-paclitaxel regimen in advanced NSCLC has a better tumor response rate and safety than solvent-based paclitaxel.However,the safety and efficacy of Nimotuzumab plus nab-paclitaxel regimen is uncertain in neoadjuvant therapy in esophageal cancer.The investigators then initiated a phase II clinical trial with Nimotuzumab plus Nab-paclitaxel/cisplatin as the neoadjuvant chemotherapy in patients with locally advanced esophageal squamous cell carcinoma to observe the efficacy and safety of the combination.

    Lay Summary

    A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus

    Sponsor / Cooperative group

    Zhejiang University

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Shawgi Sukumaran Recruitment on Hold